G1 Therapeutics Inc (GTHX)
7.15
0.00 (0.00%)
USD |
NASDAQ |
Sep 18, 16:00
G1 Therapeutics Debt to Equity Ratio: 1.802 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.802 |
| March 31, 2024 | 1.554 |
| December 31, 2023 | 1.457 |
| September 30, 2023 | 1.191 |
| June 30, 2023 | 0.8851 |
| March 31, 2023 | 1.722 |
| December 31, 2022 | 1.120 |
| September 30, 2022 | 1.666 |
| June 30, 2022 | 1.147 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.7555 |
| December 31, 2021 | 0.5238 |
| September 30, 2021 | 0.1697 |
| June 30, 2021 | 0.1412 |
| March 31, 2021 | 0.1219 |
| December 31, 2020 | 0.1122 |
| September 30, 2020 | 0.0996 |
| June 30, 2020 | 0.0954 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.0954
Minimum
Jun 2020
1.802
Maximum
Jun 2024
0.8567
Average
0.8851
Median
Jun 2023
Debt to Equity Ratio Benchmarks
| PetIQ Inc | 1.717 |
| Biomarin Pharmaceutical Inc | 0.1098 |
| Regeneron Pharmaceuticals Inc | 0.0677 |
| Verrica Pharmaceuticals Inc | -1.272 |
| Terns Pharmaceuticals Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 98.69M |
| Total Liabilities (Quarterly) | 74.10M |
| Shareholders Equity (Quarterly) | 24.59M |
| Current Ratio | 2.478 |
| Net Debt Paydown Yield | 5.52% |